Shanghai Medicilon Competitors and Similar CompaniesClear all

Shanghai Medicilon's competitors and similar companies include Corbus Pharmaceuticals, Alfasigma, Ergomed and Laurus Labs.

	Shanghai Medicilon Shanghai Medicilon (美迪西生物医药) is a contract research organization (CRO) that provides biopharmaceutical preclinical research and development solutions.	Corbus Pharmaceuticals Corbus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.	Alfasigma Alfasigma is a pharmaceutical company providing prescription and over-the-counter drugs.	Ergomed Ergomed Group is a company that provides drug development services to the pharmaceutical industry.	Laurus Labs Laurus Labs is a pharmaceutical company.
Founding Date	Founding Date 2004	Founding Date 2009	Founding Date 2015	Founding Date 1997	Founding Date 2005
Type	Type Public	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare clinical research drug development pharma
Locations	Locations Shanghai, CN HQ	Locations Norwood, US HQ	Locations Bologna, IT HQ Bruxelles, BE Issy Les Moulineaux, FR Mumbai, IN see more	Locations Guildford, GB HQ	Locations Hyderabad, IN HQ Hamburg, DE Turkapally, IN Visakhapatnam, IN Visakhapatnam, IN Visakhapatnam, IN Visakhapatnam, IN see more
Employees	Employees 2,600	Employees 14183% increase	Employees 2,5061% increase	Employees 1,800	Employees 5,75359% increase
Valuation ($)	Valuation ($) 664.4 m	Valuation ($) 195.1 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ¥1.2b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £145.3m (FY, 2022)	Revenue (est.) ₹68.1b (FY, 2026)
Cost of goods	Cost of goods ¥961.2m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods £86.1m (FY, 2022)	Cost of goods ₹27b (FY, 2026)
Gross profit	Gross profit ¥200.3m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit £60.3m (FY, 2022)	Gross profit ₹41.7b (FY, 2026)
Net income	Net income (¥167.8m) (FY, 2025)	Net income ($78.5m) (FY, 2025)	Net income N/A	Net income £15m (FY, 2022)	Net income ₹8.9b (FY, 2026)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 12.7m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 90m